Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries

[1]  J. Gisbert,et al.  ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. , 2021, Journal of Crohn's & colitis.

[2]  G. Liguori,et al.  Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  C. Taxonera,et al.  Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. , 2021, Inflammatory bowel diseases.

[4]  A. Varvarynets.  EFFECTS OF BIOLOGICAL THERAPY ON QUALITY OF LIFE AND PSYCHOEMOTIONAL STATUS OF PATIENTS WITH ULCERATIVE COLITIS , 2021, Wiadomości Lekarskie.

[5]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[6]  S. Vermeire,et al.  Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial , 2020, Journal of Crohn's & colitis.

[7]  G. Milligan,et al.  Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience , 2020, BMJ open gastroenterology.

[8]  B. Sands,et al.  Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  J. Krisam,et al.  Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study , 2020, Journal of clinical medicine.

[10]  R. Kalla,et al.  Ulcerative colitis: Recent advances in the understanding of disease pathogenesis , 2020, F1000Research.

[11]  J. Cappelleri,et al.  Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe , 2020, PloS one.

[12]  Siddharth Singh,et al.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.

[13]  Siddharth Singh,et al.  AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.

[14]  A. Cheifetz,et al.  Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. , 2019, Gastroenterology & hepatology.

[15]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[16]  A. Hartzema,et al.  Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. , 2019, Inflammatory bowel diseases.

[17]  Ashwin N. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults , 2019, The American journal of gastroenterology.

[18]  R. Palframan,et al.  Minimally Important Difference for WPAI:CD Scores: Defining Relevant Impact on Work Productivity in Active Crohn’s Disease , 2019 .

[19]  C. Mulder,et al.  Accommodations and Adaptations to Overcome Workplace Disability in Inflammatory Bowel Disease Patients: A Systematic Review , 2019, Inflammatory Intestinal Diseases.

[20]  G. Salanti,et al.  Systematic review with network meta‐analysis: the impact of medical interventions for moderate‐to‐severe ulcerative colitis on health‐related quality of life , 2018, Alimentary pharmacology & therapeutics.

[21]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[22]  S. Vermeire,et al.  Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies , 2017, Journal of Crohn's & colitis.

[23]  Siddharth Singh,et al.  Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  W. Sandborn,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[25]  P. Lefebvre,et al.  Perspectives on the Common Drug Review Process at the Canadian Agency for Drugs and Technologies in Health , 2017 .

[26]  J. Piercy,et al.  Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015 , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[27]  J. Piercy,et al.  Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme , 2016, BMJ Open.

[28]  J. Cappelleri,et al.  Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.

[29]  M. Parkes,et al.  Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease , 2016 .

[30]  J. Cappelleri,et al.  Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes , 2015, BMC Gastroenterology.

[31]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[32]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[33]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand , 2008, Current medical research and opinion.

[34]  Martin L. Brown,et al.  Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. , 2008, Clinical therapeutics.

[35]  W. Sandborn,et al.  Minimally Important Difference for WPAI:CD Scores: Defining Relevant Impact on Work Productivity in Active Crohnʼs Disease: 962 , 2007 .

[36]  J. Katz.  Management of inflammatory bowel disease in adults , 2007, Journal of digestive diseases.

[37]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[38]  Ronnie Driver,et al.  Biostatistics: a Methodology for the Health Sciences , 2005 .

[39]  E. Irvine,et al.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.

[40]  L. Fisher,et al.  Biostatistics: A Methodology for the Health Sciences , 1993 .

[41]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[42]  G. Guyatt,et al.  A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.

[43]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[44]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.